Exxua Charts a New Path in Depression Treatment Following FDA Nod

Fabre Kramer Pharmaceuticals, Inc., a Texas-based pharmaceutical firm specializing in psychotropic drug development, revealed that its groundbreaking antidepressant, Exxua (gepirone extended release) for treating major depressive disorder (MDD), received US Food and Drug Administration (FDA) approval on September 22, 2023.